Universal screening not recommended for high-risk groups
In finalizing its draft recommendations for prostate cancer screening in men ages 55 to 69, the U.S. Preventive Services Task Force (USPSTF) has put itself broadly in alignment with guidelines from other organizations.
The USPSTF now recommends that for this age group, the decision to be screened for prostate cancer with prostate-specific antigen (PSA)-based testing should be an individual one, reported USPSTF Vice Chair Alex H. Krist, MD, MPH, of the Virginia Commonwealth University in Richmond, and colleagues in JAMA.